Genetic determinants and clinical significance of circulating and tumor-specific levels of insulin-like growth factor binding protein 7 (IGFBP7) in a Swedish breast cancer cohort
(2025) In Carcinogenesis 46(2).- Abstract
Previous research indicates that insulin-like growth factor binding protein 7 (IGFBP7) protein levels in breast cancer tissue and blood are prognostic. However, genetic determinants of IGFBP7 in breast cancer remain largely unexplored. We examined IGFBP7 in a cohort of 1701 patients with a first breast cancer from Sweden, enrolled prior to surgery 2002-2016 and followed for up to 15 years. Genotyping was performed on blood samples using OncoArray. Tumor-specific protein levels of IGFBP7, insulin receptor (InsR), and IGF-I receptor (IGFIR) were assessed on tumor tissue microarrays in 964 patients. Further, 275 patients had plasma IGFBP7 levels measured. A genetic proxy marker for circulating IGFBP7 levels was constructed from five... (More)
Previous research indicates that insulin-like growth factor binding protein 7 (IGFBP7) protein levels in breast cancer tissue and blood are prognostic. However, genetic determinants of IGFBP7 in breast cancer remain largely unexplored. We examined IGFBP7 in a cohort of 1701 patients with a first breast cancer from Sweden, enrolled prior to surgery 2002-2016 and followed for up to 15 years. Genotyping was performed on blood samples using OncoArray. Tumor-specific protein levels of IGFBP7, insulin receptor (InsR), and IGF-I receptor (IGFIR) were assessed on tumor tissue microarrays in 964 patients. Further, 275 patients had plasma IGFBP7 levels measured. A genetic proxy marker for circulating IGFBP7 levels was constructed from five candidate single nucleotide polymorphisms (SNPs) (rs6852762, rs1714014, rs9992658, rs10004910, and rs4865180) based on number of recessive genotypes. Age-adjusted linear regression was used to evaluate SNPs and tumor-specific IGFBP7 levels in relation to circulating IGFBP7 levels. Cox regression adjusted for age, tumor characteristics, and adjuvant treatments was used to assess associations with clinical outcomes. Circulating and tumor-specific IGFBP7 levels were significantly positively correlated. High circulating and genetically predicted IGFBP7 levels were associated with increased risk for distant metastasis and all-cause mortality. A significant interaction between high tumor-specific IGFBP7 levels and membrane-bound InsR resulted in a four-fold increased risk of breast cancer events and distant metastases. Both measured and genetically predicted IGFBP7 levels were independent prognostic biomarkers in breast cancer.
(Less)
- author
- Godina, Christopher
LU
; Rosendahl, Ann H LU ; Gonçalves de Oliveira, Kelin LU ; Khazaei, Somayeh LU ; Björner, Sofie LU ; Jirström, Karin LU
; Isaksson, Karolin LU ; Pollak, Michael N and Jernström, Helena LU
- organization
-
- LUCC: Lund University Cancer Centre
- Cancerepidemiology and radiation
- Breastcancer
- Breast cancer prevention & intervention (research group)
- Epidemiology and pharmacogenetics (research group)
- Tumor microenvironment
- Therapeutic pathology
- Department Office of Clinical Sciences, Lund
- Lund Melanoma Study Group (research group)
- Surgery (Lund)
- EpiHealth: Epidemiology for Health
- publishing date
- 2025-04-15
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Carcinogenesis
- volume
- 46
- issue
- 2
- article number
- bgaf020
- publisher
- Oxford University Press
- external identifiers
-
- scopus:105004997227
- pmid:40230015
- ISSN
- 0143-3334
- DOI
- 10.1093/carcin/bgaf020
- language
- English
- LU publication?
- yes
- additional info
- © The Author(s) 2025. Published by Oxford University Press.
- id
- 4eb81d90-3605-49f3-8a54-3b937d9e5ca7
- date added to LUP
- 2025-04-16 08:12:29
- date last changed
- 2025-07-23 07:07:48
@article{4eb81d90-3605-49f3-8a54-3b937d9e5ca7, abstract = {{<p>Previous research indicates that insulin-like growth factor binding protein 7 (IGFBP7) protein levels in breast cancer tissue and blood are prognostic. However, genetic determinants of IGFBP7 in breast cancer remain largely unexplored. We examined IGFBP7 in a cohort of 1701 patients with a first breast cancer from Sweden, enrolled prior to surgery 2002-2016 and followed for up to 15 years. Genotyping was performed on blood samples using OncoArray. Tumor-specific protein levels of IGFBP7, insulin receptor (InsR), and IGF-I receptor (IGFIR) were assessed on tumor tissue microarrays in 964 patients. Further, 275 patients had plasma IGFBP7 levels measured. A genetic proxy marker for circulating IGFBP7 levels was constructed from five candidate single nucleotide polymorphisms (SNPs) (rs6852762, rs1714014, rs9992658, rs10004910, and rs4865180) based on number of recessive genotypes. Age-adjusted linear regression was used to evaluate SNPs and tumor-specific IGFBP7 levels in relation to circulating IGFBP7 levels. Cox regression adjusted for age, tumor characteristics, and adjuvant treatments was used to assess associations with clinical outcomes. Circulating and tumor-specific IGFBP7 levels were significantly positively correlated. High circulating and genetically predicted IGFBP7 levels were associated with increased risk for distant metastasis and all-cause mortality. A significant interaction between high tumor-specific IGFBP7 levels and membrane-bound InsR resulted in a four-fold increased risk of breast cancer events and distant metastases. Both measured and genetically predicted IGFBP7 levels were independent prognostic biomarkers in breast cancer.</p>}}, author = {{Godina, Christopher and Rosendahl, Ann H and Gonçalves de Oliveira, Kelin and Khazaei, Somayeh and Björner, Sofie and Jirström, Karin and Isaksson, Karolin and Pollak, Michael N and Jernström, Helena}}, issn = {{0143-3334}}, language = {{eng}}, month = {{04}}, number = {{2}}, publisher = {{Oxford University Press}}, series = {{Carcinogenesis}}, title = {{Genetic determinants and clinical significance of circulating and tumor-specific levels of insulin-like growth factor binding protein 7 (IGFBP7) in a Swedish breast cancer cohort}}, url = {{http://dx.doi.org/10.1093/carcin/bgaf020}}, doi = {{10.1093/carcin/bgaf020}}, volume = {{46}}, year = {{2025}}, }